Antibacterial Activity of Ticagrelor in Conventional Antiplatelet Dosages Against Antibiotic-Resistant Gram-Positive Bacteria Ticagrelor reversibly inhibits the platelet adenosine diphosphate P2Y12 receptor (P2Y12).1 It is approved for prevention of cardiovascular events in patients with atherosclerotic cardiovascular disease and shows evidence of superior clinical performance compared with other P2Y12 inhibitors. A post hoc analysis of the Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome (PLATO) trial2 revealed that patients treated with ticagrelor had a lower risk of infection-related death than those treated with clopidogrel bisulfate.3 More recently, in the Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor (XANTHIPPE) study, ticagrelor was associated with improved lung function in patients hospitalized for pneumonia.4 We therefore questioned whether ticagrelor or its metabolites could possess antimicrobial properties.

DOWNLOAD Antibacterial Activity of Ticagrelor in Conventional Antiplatelet Dosages Against Antibiotic-Resistant Gram-Positive Bacteria

آدرس

شیراز ٬ بلوار زند٬ بیمارستان نمازی٬ بخش قلب و عروق٬ انجمن قلب فارس



پست الکترونیکی

تلفن


36125609 - 071
36125601 - 071